Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.1 to v3.7.2, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:34:31.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The site footer’s revision identifier changed from v3.7.0 to v3.7.1; the study record remains unavailable with a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T22:29:20.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    35 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden message with a Home button, replacing the study content with a minimal error layout and including site footer metadata.
    Difference
    20%
    Check dated 2026-09-20T20:45:38.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    A new site revision tag, v3.6.6, was added to the footer, and references to the previous revision (v3.6.5) along with several branding/links were removed.
    Difference
    0.3%
    Check dated 2026-08-30T22:01:29.000Z thumbnail image
  6. Check
    77 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.4 to v3.6.5, indicating a minor platform update with no changes to study content or visible information.
    Difference
    0.1%
    Check dated 2026-08-09T09:20:54.000Z thumbnail image
  7. Check
    92 days ago
    Change Detected
    Summary
    Revision updated from v3.6.3 to v3.6.4, indicating a minor maintenance update to the page. This change does not modify study data, eligibility criteria, or results.
    Difference
    0.1%
    Check dated 2026-07-25T18:03:43.000Z thumbnail image

Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.